The Computational Analysis and Phytochemical Screening Targeting Dihydrolipoamide Dehydrogenase (DLD) for Alzheimer's Disease: A Molecular Dynamics Simulation Study

Dihydrolipoamide dehydrogenase DLD in Alzheimer’s disease-AD, MD simulation approach


  • Muhammad Mazhar Fareed Government College University Faisalabad


Alzheimer’s disease, Dihydrolipoamide dehydrogenase (DLD1), Molecular docking, Natural medicinal compounds, MD-simulation, Pharmacokinetics analysis.


The decreasing rate of metabolisms within the mitochondrial is connected to the progressive characterization of Alzheimer's Disease (AD). Dihydrolipoamide dehydrogenase (dld), and DLD1 are specific chemicals comprised of two enzymes/complexes of protein; pyruvate dehydrogenase and α-ketoglutarate dehydrogenase physiologically related to AD and have a noteworthy function in energy metabolism. The present computational study was designed to envisage a rational screening of natural phytochemical compounds against DLD1 in AD. The molecular docking and virtual screening approaches were adopted within the best binding active sites of DLD1 in AD to screen 15,282 medicinal phytochemicals’ libraries, which were developed from the literature search, PubChem, Zinc Database, and MPD3 Database. This docking followed by MD-simulation of the best three complexes (1-Caffeoyl-4-deoxyquinic acid, N-Butyryl Coenzyme A, Precatorine) determined through docking scores, RMSD-refine, Pharmacokinetics properties, pharmacological analysis, molinspiration, ADMET-properties, and binding energies. The top complexes with docking-S scores (-13.7117, -12.4565, -11.6440), RMSD-refine values (1.64, 0.86, 0.93), and interactive hits/residues (Arg216, Leu263, Ile125, Met262, Asp256), showed a binding affinity with another catalytic active site domain-chain A (residues 86-293). Although this in-silico work is not experimentally determined, the affinity and interactions of these selected novel compounds might help to design the therapeutics against Alzheimer’s Disease.


Download data is not yet available.


Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews Neuroscience, 8(9), 663-672.

Brown, A. M., et al. (2007). Testing for linkage and association across the dihydrolipoyl dehydrogenase gene region with Alzheimer’s disease in three sample populations. Neurochemical Research, 32(4-5), 857-869.

Carothers, D. J., Pons, G., & Patel, M. S. (1989). Dihydrolipoamide dehydrogenase: functional similarities and divergent evolution of the pyridine nucleotide-disulfide oxidoreductases. Archives of Biochemistry and Biophysics, 268(2), 409-425.

Eleazu, C., et al. (2012). Comparative study of the phytochemical composition of the leaves of five Nigerian medicinal plants. Journal of Biotechnology and Pharmaceutical Research, 3(2), 42-46.

Giuffrida, M. L., et al. (2009). β-amyloid monomers are neuroprotective. Journal of Neuroscience, 29(34), 10582-10587.

Grassi, B., et al. (1998). Faster adjustment of O2 delivery does not affect V˙ o 2 on-kinetics in isolated in situ canine muscle. Journal of Applied Physiology, 85(4), 1394-1403.

Hoyer, S. (2004). Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. European Journal of Pharmacology, 490(1-3), 115-125.

Hoyer, S., & Nitsch, R. (1989). Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. Journal of Neural Transmission, 75(3), 227-232.

Ling, Y., Morgan, K., & Kalsheker, N. (2003). Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer’s disease. The International Journal of Biochemistry & Cell Biology, 35(11), 1505-1535.

Mattson, M. P., Gleichmann, M., & Cheng, A. (2008). Mitochondria in neuroplasticity and neurological disorders. Neuron, 60(5), 748-766.

Mukhtar, M., et al. (2008). Antiviral potentials of medicinal plants. Virus Research, 131(2), 111-120.

Nag, S., et al. (2011). Nature of the amyloid-β monomer and the monomer-oligomer equilibrium. Journal of Biological Chemistry, 286(16), 13827-13833.

Ott, A., et al. (1999). Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 53(9), 1937-1937.

Perry, T., & Greig, N. H. (2002). The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. Journal of Alzheimer's Disease, 4(6), 487-496.

Reitz, C., & Mayeux, R. (2014). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical Pharmacology, 88(4), 640-651.

Ristow, M. (2004). Neurodegenerative disorders associated with diabetes mellitus. Journal of Molecular Medicine, 82(8), 510-529.

Shi, Q., et al. (2008). Novel functions of the α-ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer's disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1782(4), 229-238.

Sun, M.-K., & Alkon, D. L. (2006). Links between Alzheimer's disease and diabetes. Drugs of Today, 42(7), 481.

Taylor, M., et al. (2010). Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer’s disease. Biochemistry, 49(15), 3261-3272.

Vilalta, A., & Brown, G. C. (2014). Deoxyglucose prevents neurodegeneration in culture by eliminating microglia. Journal of Neuroinflammation, 11(1), 1-10.

Völgyi, K., et al. (2017). Mitochondrial proteome changes correlating with β-amyloid accumulation. Molecular Neurobiology, 54(3), 2060-2078.

Wang, D., et al. (2015). Role of intestinal microbiota in the generation of polyphenol‐derived phenolic acid mediated attenuation of Alzheimer's disease β‐amyloid oligomerization. Molecular Nutrition & Food Research, 59(6), 1025-1040.

Wang, J., et al. (2014). Cocoa extracts reduce oligomerization of amyloid-β: implications for cognitive improvement in Alzheimer's disease. Journal of Alzheimer's Disease, 41(2), 643-650.

Wang, J.-Z., et al. (2013). Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. Journal of Alzheimer's Disease, 33(s1), S123-S139.

Wimo, A., et al. (2017). The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer's & Dementia, 13(1), 1-7.

Yadav, R., & Agarwala, M. (2011). Phytochemical analysis of some medicinal plants. Journal of Phytology.

Yao, J., et al. (2011). 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLOS One, 6(7), e21788.

Zhang, H., et al. (2012). Proteolytic processing of Alzheimer’s β‐amyloid precursor protein. Journal of Neurochemistry: REVIEW, 120, 9-21.

Zhang, L.-F., et al. (2015). Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells. Drug Design, Development and Therapy, 9, 241.

Zhang, Y.-w., et al. (2011). APP processing in Alzheimer's disease. Molecular Brain, 4(1), 1-13.



How to Cite

Fareed, M. M. (2024). The Computational Analysis and Phytochemical Screening Targeting Dihydrolipoamide Dehydrogenase (DLD) for Alzheimer’s Disease: A Molecular Dynamics Simulation Study: Dihydrolipoamide dehydrogenase DLD in Alzheimer’s disease-AD, MD simulation approach. European Journal of Volunteering and Community-Based Projects, 1(2), 70-94. Retrieved from